Using the ScreenCell Device to Track Circulating Tumor Cells in Breast Cancer Follow-up

What this Trial Is About

Researchers are evaluating the use of liquid biopsy with ScreenCell technology to detect and measure circulating tumor cells CTCs in women during breast cancer follow-up. The study focuses on how the number of CTCs changes over time and aims to provide information on the stage and molecular characteristics of breast cancer during patient monitoring. The study involves three groups women with no cancer history confirmed by a recent negative mammogram, women with metastatic breast cancer or relapse confirmed by a positive PET scan, and women with invasive but non-metastatic breast cancer. The ScreenCell device is used on blood samples taken from participants to detect CTCs. The study is non-randomized and does not involve any masking or blinding. Participants will be followed for 9 months from enrollment to track changes in CTC levels and their molecular characteristics. Assessments include blood sample collection for CTC detection, with monitoring throughout treatment or follow-up. The primary outcome is the evolution of CTC kinetics during treatment, while secondary outcomes analyze molecular features of detected CTCs.

Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device